Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

Fudan University

Status and phase: Enrolling; Early Phase 1

Conditions: Androgenetic Alopecia (AGA)

Treatments: Drug: Oral DHA + Topical minoxidil 5%; Drug: Topical Minoxidil 5%

Study type: Interventional

Funder types: Other

Identifiers

NCT07012486

B2025-112R

Details and patient eligibility

About

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

• Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.
• Visit the clinic once every month for checkups and tests.

Enrollment: 30 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically diagnosed with androgenetic alopecia (AGA)
• No pregnancy plans within the next 6 months

Exclusion criteria

• Patients who received systemic medications for hair loss within the past 2 months
• Use of topical medication for hair loss within the past 2 weeks
• Pregnancy or lactation
• Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

30 participants in 2 patient groups

Intervention Arm

Active Comparator group

Description:

oral dihydroartemisinin (DHA) combined with topical minoxidil

Treatment:

Drug: Oral DHA + Topical minoxidil 5%

Control Arm

Other group

Description:

topical minoxidil alone

Treatment:

Drug: Topical Minoxidil 5%